Alert over sleep apnoea treatment's death rate

A sleep apnoea treatment known as adaptive servo ventilation (ASV) should no longer be used in patients with heart failure and central sleep apnoea until higher death rates have been ruled out, researchers say.

A major international trial in 1300 patients with heart failure and reduced ejection fraction unexpectedly found those treated with ASV devices had a higher mortality rate compared with a those who only received guideline-based care.

The device was intended to treat episodes of Cheyne–Stokes

Latest

Trending